Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The influenza A hemagglutinin receptor-binding site on host cells refers to the sialic acid (N-acetylneuraminic acid) residues located on the terminal ends of cell-surface glycans. These residues serve as the essential attachment point for the influenza A virus hemagglutinin (HA) protein, initiating the process of viral entry and infection [1]. The specificity of the interaction depends on the linkage of the sialic acid to the underlying galactose; human influenza viruses typically prefer alpha-2,6-linkages found in the upper respiratory tract, while avian viruses prefer alpha-2,3-linkages [2]. Because this interaction is the first step of the viral life cycle, it is a major target for therapeutic intervention. Drugs like DAS181 (Fludase) act as sialidases that enzymatically remove these receptors from the host cell surface, thereby creating a physical barrier to viral attachment [3]. This host-targeted approach is advantageous as it remains effective against various viral strains and subtypes, including those resistant to traditional neuraminidase inhibitors [4]. However, since sialic acids are involved in numerous host biological functions, such as cell signaling and protein stability, therapeutic strategies must balance efficacy with potential safety concerns [5]. Sources: [1] Skehel, J. J., & Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry. [2] Shinya, K., et al. (2006). Avian flu: influenza virus receptors in the human airway. Nature. [3] Malakhov, M. P., et al. (2006). Sialidase fusion protein as a novel broad-spectrum antiviral agent. Antimicrobial Agents and Chemotherapy. [4] Triana-Baltzer, G. B., et al. (2009). DAS181, a sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. Journal of Infectious Diseases. [5] Varki, A. (2008). Sialic acids in human health and disease. Trends in Molecular Medicine.
Enzymatic cleavage of terminal sialic acid residues from host cell surface glycoproteins and glycolipids to prevent viral attachment and entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid receptor (SA receptor) (SA receptor).